SCHEMBL20567346

SCHEMBL20567346

COc1ccc(C)c(Oc2ccc(NC(=O)C(C)N(C(=O)O)C(C)(C)C)cn2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.41
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.39
MAPT P10636 4/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 3/20 0.38
PABPC1 P11940 1/20 0.38
GFER P55789 1/20 0.38
PKM P14618 1/20 0.38
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13720861 1.00 HTR2C (0.41) HTR2CALDH1A1KMT2APOLBKDM4E
SCHEMBL13720786 0.93 KMT2A (0.41) ALDH1A1KMT2APOLBKDM4ERECQL
SCHEMBL21980921 0.93 KMT2A (0.41) ALDH1A1KMT2APOLBKDM4ERECQL
SCHEMBL13721340 0.90 ALDH1A1 (0.40) HTR2CALDH1A1KMT2APOLBRAB9A
SCHEMBL13720664 0.87 MTNR1B (0.46) ALDH1A1KMT2AMAPTGAAMEN1
SCHEMBL13720692 0.85 ALDH1A1 (0.37) HTR2CALDH1A1KMT2APOLBRAB9A
SCHEMBL21980941 0.84 KMT2A (0.47) HTR2CALDH1A1KMT2APOLBRAB9A
SCHEMBL13720953 0.84 KMT2A (0.47) HTR2CALDH1A1KMT2APOLBRAB9A
SCHEMBL13721585 0.83 XIAP (0.46) KMT2AMEN1MTNR1B
SCHEMBL13721319 0.83 KEAP1 (0.45) HTR2CALDH1A1KMT2APOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HTR2C 334/4885ALDH1A1 848/4885KMT2A 530/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HTR2C 334/4885ALDH1A1 848/4885KMT2A 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.